BMRN
Biomarin Pharmaceutical Inc
57.20$
-2.2%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 43.7% | 43.2% | 43.4% | 46.1% | 44.6% | 46.3% | 48.5% | 51.0% | 50.6% | 52.1% | 53.6% | 33.9% | |
| 11.6% | 11.0% | 10.9% | 13.8% | 9.9% | 13.5% | 14.7% | 16.3% | 16.4% | 17.3% | 25.9% | 7.5% | |
| 16.7% | 15.7% | 15.2% | 17.3% | 13.6% | 16.3% | 17.8% | 19.2% | 19.4% | 20.6% | 25.9% | 7.5% | |
| 8.5% | 9.3% | 9.3% | 9.8% | 11.3% | 9.5% | 10.3% | 11.5% | 10.4% | 12.0% | 10.5% | 9.1% | |
| 15.3% | 16.2% | 16.6% | 16.7% | 17.2% | 17.6% | 17.8% | 18.0% | 18.2% | 17.1% | 14.8% | 15.2% | |
| 15.8% | – | – | – | – | – | – | – | – | – | – | – | |
| 2.9% | 2.9% | 2.9% | 2.8% | 2.9% | 2.8% | 2.7% | 2.6% | 2.6% | 2.6% | 2.3% | 5.6% | |
| 4.5% | 4.3% | 4.1% | 3.8% | 3.8% | 3.7% | 3.5% | 3.2% | 3.1% | 2.8% | 2.4% | 41.6% | |
| 27.5% | 27.6% | 26.2% | 25.2% | 21.0% | 19.0% | 18.9% | 19.2% | 20.5% | 19.8% | 27.7% | 46.1% | |
| 17.2% | 17.2% | 15.8% | 15.1% | 10.4% | 8.7% | 8.8% | 9.2% | 10.5% | 10.0% | 9.2% | 14.2% | |
| 7.4% | 7.3% | 7.3% | 7.2% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 0.1% | 5.8% | |
| 4.5% | 4.6% | 4.3% | 3.6% | 4.6% | 3.4% | 4.1% | 4.2% | 5.1% | 4.1% | 4.6% | 3.5% | |
| 8.8% | 8.7% | 8.6% | 8.4% | 8.7% | 8.5% | 8.3% | 8.0% | 7.8% | 7.9% | 16.6% | 30.1% | |
| 72.5% | 72.4% | 73.8% | 74.8% | 79.0% | 81.0% | 81.1% | 80.8% | 79.5% | 80.2% | 72.3% | 53.9% | |
| -9.5% | -9.1% | -7.8% | -6.0% | -4.7% | -2.8% | -0.1% | 3.1% | 2.6% | 2.0% | 3.0% | 2.6% | |
| 2.8% | 2.8% | 2.9% | 2.8% | 2.9% | 2.8% | 2.7% | 2.6% | 2.5% | 2.6% | 2.3% | 1.7% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.